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Background
The underlying rationale of platelet rich plasma (PRP) therapy is that an injection of con-
centrated PRP at the site of injury may promote tissue repair via cytokine release from 
platelets. The molecular mechanisms of PRP therapy in the skin wound healing process 
are not well understood at present, and would benefit from clarification.
Methods
PRP was stimulated with angonists for 5 min, and cytokine profile analysis was performed. 
To investigate the wound healing activity of PRP, cell proliferation and migration analyses 
were performed in skin cells. The effects of PRP were analyzed on the expression and 
activity of matrix metalloproteinase (MMP)-1, -2, -9, and the activation of transcription 
factors.
Results
Thrombin was found to be a strong stimulator of PRP activation to release growth factors 
and chemokines. PRP induced cell proliferation and migration in HUVECs, HaCaT cells, 
and HDFs, as well as MMP-1and MMP-9 expression in HaCaT cells, but PRP did not have 
a significant effect on the expression or activity of MMPs in HDFs. The transcription fac-
tors, including signal transducer and activator of transcription-3 (STAT-3) were found to 
be phosphorylated following PRP treatment in HaCaT cells.
Conclusion
In this study, we have identified the cytokine profile of activated PRP after agonist 
stimulation. We have shown that PRP plays an active role in promoting the proliferation 
and migration of skin cells via the regulation of MMPs, and this may be applicable to the 
future development of PRP therapeutics to enhance skin wound healing.
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INTRODUCTION
The accumulation of platelets at sites of injury plays a 
critical role in hemostasis and atherothrombosis [1]. The 
adhesion of platelets to collagen exposed following the injury 
of endothelial cells initiates platelet activation and ag-
gregation, and finally leads to the formation of a stable fibrin 
clot [2-4]. However, the function of platelet rich plasma 
(PRP) in the wound healing process has not yet been clearly 
elucidated.
Anuclear platelets contain several types of granules in-
volved in coagulation, inflammation, atherosclerosis, anti-
microbial host defense, and angiogenesis [5, 6]. Platelet-de-
rived growth factor (PDGF), transforming growth factor-β 
(TGF-β), vascular endothelial growth factor (VEGF), basic 
fibroblast growth factor (bFGF), epidermal growth factor 
(EGF), and insulin-like growth factor (IGF) released from 
α-granules play a pivotal role in cell proliferation, migration, 
and differentiation. Adenosine diphosphate (ADP), seroto-
nin, and calcium released from dense granules are key ele-
ments in the coagulation cascade and the recruitment of 
new platelets [7, 8]. Antiplatelet agents such as aspirin are 
targeted to block the formation of thromboxane A2 (TXA2), Korean J Hematol 2011;46:265-73.
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whilst the P2Y12 receptor antagonist clopidogrel, used in 
patients with coronary artery disease, inhibits ADP stimula-
tion. ADP has an autocrine effect on promoting stable platelet 
aggregation by interacting with ADP-specific receptors 
(P2Y1 and P2Y12) on the platelet surface. ADP also has 
a paracrine effect by binding to ADP receptors on the surface 
of neighboring platelets, thereby amplifying platelet activa-
tion induced by other agonists. Platelets undoubtedly play 
a major role in pathogenic developments in the cardiova-
scular system. However, several lines of evidence suggest 
that platelets may also promote the wound healing processes.
PRP therapy is receiving growing attention in the fields 
of orthopedics, sports-related injuries, cancer biology, and 
dermatology. The underlying rationale of PRP therapy is 
that an injection of concentrated PRP at sites of injury may 
spur tissue repair via the release of growth factors from 
platelets. For successful wound healing, the turnover and 
remodeling of the extracellular matrix (ECM) must be ex-
quisitely controlled, and the importance of biochemical me-
diators in tissue repair and homeostasis has been well demon-
strated [9, 10]. In vivo and in vitro studies show that MMPs 
are frequently found in tissues undergoing repair or remodel-
ing, and also in human atherosclerotic lesions [11-13]. Studies 
by Wang et al. and de Mos et al. have shown that PRP 
treatment increases cell proliferation, collagen production, 
and MMP expression in human tenocytes, which suggest 
that PRP might be a candidate as a future therapy for tendon 
regeneration [14, 15]. In human gingival fibroblasts, PRP 
stimulates membrane-type matrix metalloproteinase-1 (MT- 
MMP-1) and tissue inhibitor of metalloproteinase-2 (TIMP- 
2) production, cell migration/invasion, and myofibroblastic 
differentiation, and has positive effects in gingival repair 
[16]. In contrast, a recent study reported that PRP injections 
in chronic Achilles tendinopathy did not produce any sig-
nificant improvement of symptoms [17]. Therefore, although 
some favorable results have been shown for PRP therapy 
in wound healing, the efficacy and underlying mechanisms 
of PRP are yet to be fully clarified.
In this study, we aimed to characterize PRP activation 
and test the feasibility of PRP therapy in skin wound healing.
MATERIALS AND METHODS
1. Materials
Dulbecco’s modified Eagle’s medium (DMEM) and fetal 
bovine serum (FBS) were obtained from Hyclone (Logan, 
UT, USA). Endothelial cell growth medium-2 (EGM-2) 
Bulletkit was purchased from Lonza (Walkersville, MD, 
USA). MMP-1 antibody was bought from Calbiochem (San 
Diego, CA, USA). Anti-phospho-STAT3 (Tyr705), anti-phos-
pho- c-Jun N-terminal kinase (JNK), and anti-phospho- nu-
clear factor kappa-light-chain-enhancer of activated B cells 
(NF-κB) antibodies were purchased from Cell Signaling 
Technology (Beverly, MA, USA), and anti-β actin antibody 
was obtained from Santa Cruz Biotechnology (Santa Cruz, 
CA, USA).
2. PRP isolation and stimulation with agonists
Ten healthy volunteers each donated 10 mL of whole 
blood. The donors gave informed consent for participation 
in the study. For the preparation of PRP, 10 mL of blood 
was collected in an acid citrate dextrose (ACD-A) tube coated 
with anti-coagulating agent (Sigma-Aldrich, 10% (v/v)) and 
centrifuged at 250×g for 15 min at 37
oC. The supernatant 
fraction was harvested and incubated for 10 min at 37
oC, 
then centrifuged at 1,900×g for 8 min. Pellets were re-
suspended in Tyrode’s buffer (137 mM NaCl, 2.7 mM KCl, 
16 mM NaHCO3, 5 mM MgCl2, 3.5 mM HEPES, 2.5 mM 
CaCl2, 5.5 mM glucose, 2 mg/mL BSA, pH 7.4) containing 
10 U/mL heparin and 0.5 μM PGI2, and incubated for 10 
min at 37
oC. After centrifugation at 1,900×g for 8 min, 
Tyrode’s buffer containing 0.02 U/mL of heparin was added 
to resuspend pellets and obtain PRP. Fluorescence-activated 
cell sorting (FACS) analysis was performed to stain P-selectin 
on platelets after stimulation with thrombin, and it was 
confirmed that 90% of the cell population expressed P- 
selectin. PRP containing 1.5×10
9 platelets/mL was prepared 
and used for further study. PRP stimulation was performed 
for 5 min with 5 μM ADP, 1% Ca
2＋, 20 μg/mL collagen, 
or 20 U/mL thrombin.
3. Multiplex analysis
To analyze cytokines released from PRP, a multiplex MAP 
human cytokine/chemokine immunoassay (Millipore, Bille-
rica, MA, USA) was used following the manufacturer’s proto-
col (Luminex 100
TM IS Total System, XMAP Technology 
with MasterPlex software, Millipore, Billerica, MA, USA). 
Forty growth factors, inflammatory cytokines, and chemo-
kines, including PDGF-AA, AB/BB, TGF-α, VEGF, FGF, eo-
taxin, granulocyte- macrophage colony-stimulating factor 
(GM-CSF), interferon (IFN)-α2, IFN-γ, interleukin (IL)-10, 
IL-12, IL-1α, IL-1β, IL-1Rα, IL-2, IL-6, interferon gam-
ma-induced protein 10 (IP-10), monocyte chemoattractant 
protein (MCP)-1, Regulated on activation normal T cell ex-
pressed and secreted (RANTES), and tumor necrosis factor-α 
(TNF-α), were quantitatively analyzed. For the analysis of 
TGF-β1, 2, and 3 isoforms, multiplex TGF-β1, 2, 3 immuno-
assay (Millipore, Billerica, MA, USA) was used following 
the manufacturer’s protocol.
4. Cell culture
HUVECs were kindly gifted by Dr. Y.S. Choi (CHA 
University, Seoul, Korea) and cultured in endothelial cell 
growth medium (EGM) supplemented with growth factors, 
10% FBS, and 1% penicillin/streptomycin solution (10,000 
IU/mL). HaCaT cells (an immortalized keratinocyte cell line) 
were kindly gifted from Dr H.K. Lee (Yonsei University, 
Seoul, Korea), and HDFs were purchased from BioBud Co. 
(Seungnam, Korea). HaCaT cells and HDFs were cultured 
in DMEM (Sciencell, USA) containing 10% fetal bovine se-
rum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin 
(GIBCO) at 37
oC, 5% CO2. HUVEC, and HDF cultures used 
for the study were passage 8 or less.Korean J Hematol 2011;46:265-73.
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5. Cell proliferation assay
HUVECs were plated on a 1% gelatin-coated plate at a 
density of 40,000 cells/35-mm dish HaCaT cells were plated 
at a density of 50,000 cells/35-mm dish. The following day, 
cells were starved with serum-free medium for 24 hr. The 
culture medium was then replaced with fresh serum-free 
medium, and 200 μL of PRP was added (10% v/v). After 
incubation for 24 hr, cells were washed with PBS 3 times, 
trypsinized, and counted using a hemocytometer.
6. Cell migration assay
Cell migration was assessed by scratch wound assay [18]. 
Briefly, HaCaT cells were plated at a density of 80,000 
cells/35-mm dish, and HDFs were plated at a density of 
50,000 cells/35-mm dish. The following day, culture medium 
was replaced with fresh serum-free DMEM, and scratch 
wounds were created in a cell monolayer using a sterile 
pipette tip. After washing away suspended cells, the culture 
medium was replaced with fresh serum-free medium and 
200 μL of PRP was added (10% v/v). After 24 hr, the wound 
width was estimated using a light microscope (Nikon, Japan) 
equipped with a digital camera, and 4 measurements of 
wound width were made at randomly chosen points. The 
extent of wound closure was presented as the percentage 
by which the original scratch width had decreased at each 
measured time point.
7. Zymography
Two mL of conditioned media was concentrated to 500 μL 
by Vivaspin 500 (Satorius Stedim Biotech, Goettingen, 
Germany), and then 10 μL was loaded onto a 10% SDS-poly-
acrylamide gel containing 1 mg/mL gelatin. The gel was 
run in Tris/glycine buffer for 4 hr, and then incubated in 
2.5% Triton X-100 solution for 15 min twice to remove 
SDS. To detect gelatinase activity, the gel was incubated 
in reaction buffer containing 50 mM Tris- HCl (pH 7.4), 
10 mM CaCl2, and 0.05% Brij 35 overnight at 37
oC. The 
gelatinolytic activity was shown by staining with 0.1% (w/v) 
Coomassie Brilliant Blue R-250, 10% (v/v) glacial acetic acid, 
and 30% (v/v) methanol, followed by destaining with 10% 
(v/v) acetic acid and 30% (v/v) methanol.
8. Western blot analysis
Proteins were extracted with urea lysis buffer (4 M urea, 
0.5% SDS, 0.5% Nonidet P-40, 100 mM Tris (pH 7.4) and 
5 mM EDTA). Cell lysates were centrifuged, and supernatants 
containing soluble proteins were collected and subjected to 
sodium dodecyl sulfate-polyacrylamide gel electrophoresis 
(SDS-PAGE). Separated proteins were then transferred onto 
0.45-μm PVDF membranes. Blots were blocked with TBST 
(10 mM Tris-base, 100 mM NaCl, and 0.01% Tween 20) 
containing 5% bovine serum albumin for 1 hr, and then 
probed with corresponding antibodies. Membranes were in-
cubated with HRP-coupled appropriate secondary antibodies 
for 1 hr, and immunoreactive signals were detected by using 
the ECL detection kit (GE healthcare).
9. Statistical analysis
For cell proliferation and cell migration assays, each ex-
periment was repeated at least three times. The experimental 
data were analyzed by a one-way analysis of variance 
(ANOVA) or student t test. Statistical analysis was performed 
using Microsoft Exel Program. Data were presented as 
mean±SD, and P＜0.05 was considered statistically signifi-
cant.
RESULTS
1. Cytokine profiles released by PRP after agonist stimulation
PRP is considered to be a rich source of cytokines (growth 
factors/chemokines), thus, we characterized growth factor 
profiles after stimulation with agonists. One milliliter of 
resting PRP containing 1.5×10
9 platelets was stimulated with 
5 μM ADP, 20 μg/mL collagen, 1% Ca
2＋, or 20 U/mL throm-
bin for 5 min. After centrifugation at 12,000×g for 30 min, 
supernatants were collected, and growth factor analysis was 
performed using a multiplex human cytokine/chemokine 
immunoassay system (Millipore Co, Billerica, MA, USA). 
Our study showed that thrombin acted as a powerful stim-
ulator for the release of PDGF-AB/BB (＞10,000 pg/mL), 
PDGF-AA (＞10,000 pg/mL), and bFGF (370 pg/mL). 
However, the release of VEGF was negligible, and neither 
EGF nor IGF was detected following thrombin stimulation. 
When PRP was stimulated with ADP, collagen, or Ca
2＋, 
t h e  le v el s o f  re le ased  P DGF-A A ,  A B /B B,  an d b FGF we re 
relatively lower than in thrombin-stimulated PRP super-
natants (Fig. 1A). This study indicates that the activation 
of 2 thrombin receptors, protease activated receptor type 
1 (PAR-1) and PAR-4 on the platelet surface [19] occurred 
within 5 min. However, PRP activation was slower in re-
sponse to ADP, Ca
2＋, and collagen, indicating differences 
in signaling dynamics between the platelet membrane re-
ceptors for these agonists. In an analysis of chemokine pro-
files, thrombin again acted as a strong stimulator for chemo-
kine release by PRP. RANTES, GRO (cotton rat growth-regu-
lated protein), and soluble CD40 ligand (sCD40L) were the 
3 most abundantly expressed chemokines, with levels ranging 
between 2,000 pg/mL and 5,000 pg/mL. As expected, the 
highest level of RANTES release was observed by thrombin 
stimulation (3,228 pg/mL). This effect was not specific to 
thrombin, since unstimulated PRP, as well as PRP stimulated 
with ADP, Ca
2＋, or collagen, also released RANTES to con-
centrations ≥2,500 pg/mL. RANTES in α-granules of plate-
lets is known to be released during the acute stages of in-
flammation and is a potent chemoattractant for T cells, mono-
cytes, natural killer cells, basophils, and eosinophils [20]. 
It is notable that unstimulated PRP releases a high level 
of RANTES, as this indicates that the RANTES release from 
P R P  i s  l e s s  d e p e n d e n t  o n  a g onist stimulation than other 
cytokines/chemokines. In contrast, the release of sCD40L 
(3,418 pg/mL) and GRO (3,895 pg/mL) from PRP was specific 
to thrombin stimulation (Fig. 1B). Platelets are a major source 
of sCD40L, and binding of sCD40L to CD40 receptor initiates Korean J Hematol 2011;46:265-73.
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Fig. 1. Cytokine profiles released by PRP after agonist stimulation. 
One mL of resting PRP containing 1.5×10
9 platelets was 
stimulated with 5 μM ADP, 20 μg/mL collagen, 1% Ca
2＋, or 20 
U/mL thrombin for 5 min. The released growth factors (A), 
chemokines (B), and TGF-βs (C) were measured using a multiplex 
human cytokine/chemokine immunoassay system.
inflammatory processes; thus, the pharmaceutical inhibition 
of sCD40L is being vigorously pursued as a potential avenue 
for the prevention of cardiovascular disease [21]. GRO, an-
other chemokine stored in platelet α-granules, is a member 
of the CXC chemokine family, which also includes IL-4, 
platelet factor 4 (PF4), and macrophage inflammatory protein 
2 (MIP-2). GRO is expressed in macrophages, endothelial 
cells, and fibroblasts, but the functions of GRO are not well 
understood at present, although increased serum levels of 
GRO were observed in women with preeclampsia [22]. In 
our analysis of TGF-β isoforms, thrombin was found to stim-
ulate the release of TGF-β1 (2,435 pg/mL) and TGF-β2 (103.5 
pg/mL). However, neither TGF-β3 nor TGF-α was released 
from PRP stimulated with thrombin, ADP, Ca
2＋, or collagen. 
PRP was mildly stimulated to release TGF-β1 (100 pg/mL) 
by ADP, Ca
2＋, and collagen (Fig. 1C).
2. PRP-induced cell proliferation in HUVECs and HaCaT cells
The proliferation of skin cells is an active process in wound 
healing, in which coordinated upregulations are seen for 
PDGF, TGF-β, VEGF, bFGF, keratinocyte growth factor 
(KGF), and hepatocyte growth factor (HGF) [23]. On the 
basis of the results of our previous experiments, which 
showed a large release of growth factors and chemokines 
from both unstimulated and agonist-stimulated PRP, we fur-
ther investigated the effects of PRP on cell proliferation. 
When HUVECs were treated with PRP for 24 hr, cell pro-
liferation was increased 7-fold compared to serum-free con-
trols (P＜0.05, N=3). Surprisingly, there were no significant 
differences in cell proliferation rates between unstimulated 
PRP, and PRP stimulated with thrombin, ADP, or collagen. 
However, treatment of HUVECs with Ca
2＋ stimulated PRP 
significantly induced HUVEC proliferation. Ca
2＋ treatment 
without PRP treatment did not have any effect on HUVEC 
proliferation (data not shown). For HaCaT cells, we only 
tested the effect of unstimulated PRP on cell proliferation. 
The HaCaT cell proliferation rate was increased 5-fold by 
PRP compared to serum-free controls (P＜0.05, N=4) (Fig. 
2). This result is encouraging, because PRP itself may be 
safe to apply for therapeutics, while PRP agonists could 
cause adverse non-target effects. For example, treatment with 
bovine thrombin as a potent platelet activator can cause 
the development of antibodies against thrombin, which lead 
to severe postoperative bleeding following bypass graft sur-
gery to treat thrombosis in animal studies [24].
3. PRP-induced cell migration in skin cells
As cell motility and migration play pivotal roles in skin 
wound healing, we investigated the effect of PRP on cell 
migration by scratch wound assay. When HaCaT cells and Korean J Hematol 2011;46:265-73.
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Fig. 2. Effects of PRP on cell proliferation. HUVECs (A) and HaCaT cells (B) were starved with serum-free medium for 24 hr, and then replaced with
fresh serum-free medium and incubated for 24 hr with 200 μL of PRP (10% v/v), which had previously been stimulated with 5 μM ADP, 20 μg/mL
collagen, 1% Ca
2＋, or 20 U/mL thrombin for 5 min. Cells were then harvested and counted by a hemocytometer. Each treatment was performed
in triplicate, and data are presented as means±S.D.
Fig. 3. Effects of PRP on the migration of skin cells. Scratch wounds were created in cell monolayers of HaCaT cells (A) and HDFs (B) using a sterile
pipette tip. After washing away suspended cells, cells were replaced with fresh serum-free medium and 200 μL of PRP was added (10% v/v) for 24 
hr. The extent of wound closure was presented as the percentage by which the original scratch width had decreased at each measured time point.
Experiments were performed in duplicate, and data are presented as means±S.D.
HDFs were treated with PRP for 24 hr, cell migration was 
increased by 60% in HaCaT cells (P＜0.05, N=4) and 35% 
in HDFs (P＜0.05, N=3) (Fig. 3). As PDGF-AA is a key 
chemoattractant in the process of tissue repair, we consider 
that PDGF-AA released from PRP may have played a role 
in inducing the migration of HDFs in this experiment [25]. Korean J Hematol 2011;46:265-73.
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Fig. 4. Effects of PRP on the activity 
of MMP-1, 2, and 9 in skin cells. 
HaCaT cells (A) and HDFs (B) were
starved with serum-free medium 
for 24 hr, then replaced with fresh 
serum-free medium and incubated
with 200 μL of PRP (10：1, v/v) for
48 hr. The medium was concent-
rated, MMP-2 and MMP-9 activi-
ties were analyzed by gelatin zy-
mography, and MMP-1 expression 
was analyzed by Western blotting.
Fig. 5. Effects of PRP on the activation of STAT-3, JNK, and NF-κB in 
HaCaT cells. HaCaT cells were starved with serum-free medium for 48
hr, and fed with by medium replacement with fresh serum-free 
medium. Cells were then treated with 200 μL PRP (10% v/v) for 0, 5, 15,
30, 60, or 180 min. Cell lysates were analyzed by Western blotting with
anti-phospho-STAT-3, phospho-JNK, and phospho-NF-κB antibodies.
However, an effect of PDGF-AA on the migration of HaCaT 
cells can be ruled out, since HaCaT cells do not express 
PDGF receptors on the cell surface [26]. Instead, TGF-β1 
released from PRP is more likely to have been responsible 
for the migration of HaCaT cells via epithelial-to-mesen-
chymal transformation (EMT) [27].
4. The induction of MMP expression and activity in skin cells
Analysis of MMP expression has shown that MMP-1, -2, 
-3, -9, -10, and -14 are prevalently expressed during the 
skin wound healing process [28]. HaCaT cells were plated 
at a density of 300,000 cells/60-mm dish, and HDFs were 
plated at a density of 200,000 cells/60-mm dish in DMEM 
containing 10% FBS and 1% P/S. The following day, cells 
were starved with serum-free medium for 24 hr. Culture 
media were then replaced with fresh serum-free medium, 
and cells were incubated with 200 μL PRP (10% v/v) for 
48 hr. Culture media were concentrated, MMP-2 and -9 
were analyzed by gelatin zymography, and MMP-1 was ana-
lyzed by Western blotting. Our study showed that un-
stimulated PRP contained detectable levels of active MMP-9 
and MMP-2. In HaCaT cells, treatment with PRP induced 
MMP-9 activity but did not have any effect on MMP-2 
activity. In addition, MMP-1 expression was observed in 
unstimulated PRP, and treatment with PRP induced MMP-1 
expression in HaCaT cells. However, PRP treatment did 
not have any significant effect on MMP-1, MMP-2, or 
MMP-9 activity in HDFs. Our study suggests that the effects 
of PRP on the regulation of MMP expression differ between 
HaCaT cells and HDFs (Fig. 4).
5. PRP-induced activation of STAT-3, JNK, and NF-κB in skin 
cells
To investigate the regulation by PRP of transcription fac-
tors capable of transactivation at MMP promoters, we ana-
lyzed the activation of STAT-3, activator protein-1 (AP-1) 
and NF-κB by Western blotting using phospho-specific anti-
bodies [29]. HaCaT cells were plated at a density of 300,000 
cells/35-mm dish in DMEM containing 10% FBS and 1% 
P/S. The following day, cells were starved with serum-free 
medium for 48 hr. The culture medium was then replaced 
with fresh serum-free medium, and 200 μL PRP (10%, v/v) 
was added for 0, 5, 15, 30, 60, or 180 min. Following PRP 
incubations, cell lysates were prepared, and 40 μg protein 
was analyzed by Western blotting with anti-phospho- 
STAT-3, phospho-JNK and phospho-NF-κB antibodies. We 
found that PRP treatment induced the activation of STAT-3 
by phosphorylation of tyr-705 from 5-30 min. A STAT-3 
binding site is located in the promoter region of MMP-1 
[29]. We found that PRP treatment induced the phosphor-
ylation of JNK at 30 min, which may be responsible for 
MMP-1 and MMP-9 induction, as AP-1 binding sites are 
found in the promoter regions of MMP-1, -2, and -9. The 
activation of NF-κB by PRP was initiated at 5 min and 
sustained till 60 min. As NF-κB binding sites are also located 
in the promoter regions of MMP-1 and MMP-9, we assume 
that the activation of NF-κB may contribute to the induction 
of MMP-1 and MMP-9 expression (Fig. 5). Studies using 
specific inhibitors for these transcription factors may be able 
to further elucidate the mechanisms of MMP regulation by 
PRP treatment.
DISCUSSION
In this study, we hypothesized that the content of cyto-
kines in PRP may have a favorable effect on skin wound Korean J Hematol 2011;46:265-73.
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Fig. 6. A schematic diagram of the 
mechanisms by which PRP pro-
motes wound healing at sites of 
injury.
healing, including cell proliferation, cell migration, and regu-
lation of MMPs. Our result showed that thrombin was a 
powerful agonist for the induction of the release of growth 
factors and chemokines by PRP compared to ADP, Ca
2＋, 
or collagen. Although platelet α-granules are known to con-
tain various growth factors, we found that the growth factors 
released from PRP stimulated with thrombin for 5 min were 
mostly PDGF-AB/PDGF-BB (＞10,000 pg/mL), PDGF-AA 
(＞10,000 pg/mL), TGF-β1 (2,435 pg/mL), and bFGF (370 
pg/mL). However, only a negligible amount of VEGF was 
released. Surprisingly, stimulation with ADP, Ca
2＋, or colla-
gen had only a very mild effect, or no effect on the release 
of growth factors from PRP (Fig. 1). We assume that 5 min 
duration for PRP stimulation with agonists may not be long 
enough to trigger α-degranulation, except for thrombin, 
which acts through PAR-1 and PAR-4 receptors on the plate-
let surface [19]. Accordingly, prior studies have reported 
that an almost complete release of growth factors occurs 
from PRP stimulated with thrombin within the first few 
hours, and thrombin leads to FGF degradation and decreased 
levels of FGF in chronic wounds [30-32]. In addition, 
Harrison et al. showed that the use of thrombin as an activator 
results in an immediate release of PDGF and TGF-β1, and 
the use of collagen as an activator results in a cumulative 
release of TGF-β1 from PRP, which suggests that intricate 
kinetics of growth factor release differ between agonists [33]. 
Thus, allowing sufficient time for agonists to access platelet 
surface receptors would be critical for platelet degranulation, 
and the kinetics of growth factor release should be considered 
in order to achieve maximum efficacy for PRP therapeutics.
In our chemokine analysis, we found that the levels of 
RANTES, sCD40L, and GRO released from PRP were highest 
after thrombin stimulation. Interestingly, the levels of 
RANTES were not significantly different between un-
stimulated PRP and agonist-stimulated PRP, and un-
stimulated PRP released high levels of RANTES (2,500 
pg/mL). It has been suggested that the release of RANTES, 
CD40L, and GRO may be correlated. For example, in women 
with preeclampsia, levels of RANTES, sCD40L, and GRO 
were elevated together [22]. However, our study implies 
that the mechanisms of RANTES release from PRP are differ-
ent from those of CD40L or GRO release. Furthermore, it 
is also suggested that circulating platelet microparticles 
(PMPs) serve as the transcellular delivery system for RANTES 
[34]. PMPs are membrane vesicles shed from platelets, which 
range from 0.1 to 1.0 μm in diameter. PMP shedding from 
platelets is known to be stimulated by thrombin or collagen 
[35]. Choi et al. reported that sCD40L release from platelets 
is mediated by the interaction of MMP-2 with glycoprotein 
IIIa (GPIIIa) [36]. These data are supported by the ob-
servation that sCD40L levels are effectively reduced by in-
hibitors of GPIIb/IIIa both in vitro and In vivo, while the 
GRO is also localized to GPIIIa [37, 38]. Taken together, 
it is highly possible that GRO and sCD40L may associate 
with GPIIIa and interact with each other during platelet 
activation.
PDGF and TGF-β1 actively participate in wound healing 
processes involving cell proliferation and migration. To in-
vestigate the effects of PRP on the skin wound healing proc-
ess, we first tested its effect on HUVECs and HaCaT cells. 
When PRP stimulated with ADP, Ca
2＋, collagen, or throm-
bin was incubated with HUVECs, unstimulated PRP induced 
HUVEC proliferation 7-fold compared to serum-free 
controls. Surprisingly, thrombin-stimulated PRP did not 
show any significant effect on HUVEC proliferation; neither 
did ADP nor collagen-stimulated PRP (Fig. 2). The reasons 
for this may be as follows: based on our results, PRP stimu-
lated with thrombin releases a large amount of cytokines 
within 5 min, and as platelets are anuclear, it is very likely 
that the released cytokines were already stored in platelet Korean J Hematol 2011;46:265-73.
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granules, as the de novo biosynthesis of cytokines could 
not occur without nuclei. This means that unstimulated PRP, 
or PRP stimulated with ADP or collagen, contained the 
same amount of stored cytokines as the PRP stimulated by 
thrombin, but the release of these stored cytokines from 
platelets was more highly stimulated by thrombin. Thus, 
during the 24 hr incubation period with PRP for cell pro-
liferation experiments, physical interactions between cells 
and platelets may have triggered cytokine release from plate-
lets, leading to a similar stimulation of cell proliferation. 
This is encouraging, because application of PRP at injury 
sites may cause the spontaneous activation of PRP, leading 
to the release of growth factors needed for cell proliferation 
in wound healing. This hypothesis is also supported by the 
increased cell migration induced by PRP in HaCaT cells 
(Fig. 3).
Kalvegren  et al. showed that platelets induce the ex-
pression of MMP-1 and MMP-2, but not MMP-9 when ana-
lyzed by immunocytochemistry, and platelets release sig-
nificant amounts of MMP-1 and MMP-2 when stimulated 
with collagen or thrombin [39]. According to Cecchetti et 
al., megakaryocytes contain transcripts of MMP-1, -2, and 
-9, but platelets do not contain MMP-2 transcripts [40]. 
Our study showed that unstimulated PRP contained active 
MMP-1, -2, and -9, and PRP treatment induced the ex-
pression of MMP-1 and MMP-9 by HaCaT cells. In contrast, 
treatment with PRP did not have any effect on MMP ex-
pression in HDFs (Fig. 4). Interestingly, Choi et al. showed 
that the inhibition of either platelet-derived MMP-2 activity 
or binding between MMP-2 and integrins, leads to significant 
reductions in platelet activation and the release of sCD40L 
by platelets [36]. These results imply that MMPs in PRP 
may have roles beyond extracellular matrix turnover, which 
may include interactions with growth factors or chemokines.
In summary, we have determined the cytokine profile 
of activated PRP after agonist stimulation. We have also 
shown that PRP has an active role in inducing proliferation 
and migration in skin cells, which suggests that PRP is a 
promising candidate as a therapeutic agent to promote and 
enhance skin wound healing (Fig. 6).
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